2012 Merit Award Recipients Present Research at Annual Meeting: Monday, June 4
Merit Awards recognize the work of oncology fellows who are first authors of outstanding Meeting abstracts. Abstracts eligible for Merit Award consideration are evaluated during the normal abstract review period by the Scientific Program Committee. The monetary awards are provided by the Conquer Cancer Foundation® and are intended to aid young physicians with travel expenses for the Annual Meeting. More importantly, the award recognition supports further research in clinical oncology.
A complete list of all Merit Award recipients who will present research today follows, and includes the time and location of each session in chronologic order.
Fernanda Arnaldez, MD
National Cancer Institute
“ Identification of TNK2 as a critical kinase in rhabdomyosarcoma through a loss of function shRNA screen.” (Abstract 9511)
Oral Abstract Session, Pediatric Oncology
8:00 AM-11:00 AM; S504
Eliezer Van Allen, MD
Dana-Farber Cancer Institute
“A heuristic platform for clinical interpretation of cancer genome sequencing data.” (Abstract 10502)
Oral Abstract Session, Tumor Biology
8:00 AM-11:00 AM; S100bc
Joanne Ngeow, MD
National Cancer Center
“Use of PTEN protein dosage to predict for underlying germ-line PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.” (Abstract 1508)
Oral Abstract Session, Cancer Prevention/Epidemiology
8:00 AM-11:00 AM; S100a
Emmanuelle Godefroy, PhD
New York University
“Effect of matrix metalloproteinase-2 on antitumor immunity.” (Abstract 2570)
General Poster Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
8:00 AM-12:00 PM; S Hall A2
Jennifer Rauw, MD
University of Toronto
“Does the addition of molecular targeted therapy to standard treatments lead to better or worse outcomes overall? A systematic review of EGFR-targeted therapies used in combination with standard treatments.” (Abstract 2572)
General Poster Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
8:00 AM-12:00 PM; S Hall A2
Bamidele Adesunloye, MD, MS
National Cancer Institute, National Institutes of Health
“Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).” (Abstract 4569)
Poster Discussion Session, Genitourinary Cancer
8:00 AM-12:00 PM; E450a
Channing Paller, MD
The Johns Hopkins Hospital
“The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy.” (Abstract 4559)
Poster Discussion Session, Genitourinary Cancer
8:00 AM-12:00 PM; E450a
Adrian Fairey, MD, MS
University of Southern California
“Generation of a prognostic cancer stem-like gene expression signature in men undergoing radical prostatectomy for localized prostate cancer.” (Abstract 4563)
Poster Discussion Session, Genitourinary Cancer
8:00 AM-12:00 PM; E450a
Cullen Taniguchi, MD, PhD
Stanford University Medical Center
“Intestinal HIF-2 to protect against radiation-induced gastrointestinal syndrome.” (Abstract 10629)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Philip Lammers, MD
Vanderbilt University Medical Center
“Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).” (Abstract 6038)
General Poster Session, Health Services Research
1:15 PM-5:15 PM; S Hall A2
Bernadette Jaeger, MD
Department of Gynecology and Obstetrics, Ludwig-Maximilians-University
“HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.” (Abstract 10540)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Komal Jhaveri, MD
Memorial Sloan-Kettering Cancer Center
“Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i).” (Abstract 10618)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Ana Custodio, MD
La Paz University Hospital
“Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study.” (Abstract 10547)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Cliona Grant, MD
National Cancer Institute
“Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).” (Abstract 8051)
General Poster Session, Lymphoma and Plasma Cell Disorders
1:15 PM-5:15 PM; S Hall A2
Brent Hanks, MD, PhD
Duke University Medical Center
“Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy.” (Abstract 10563)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Katherine Reeder-Hayes, MD, MBA
Cecil G Sheps Center for Health Services Research
“Cost-effectiveness of adjuvant radiotherapy for older women with early hormone-receptor positive breast cancer.” (Abstract 6096)
General Poster Session, Health Services Research
1:15 PM-5:15 PM; S Hall A2
Mona Lisa Alattar, MD
University of Texas at Houston Health Science Center
“Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.” (Abstract 6558)
General Poster Session, Leukemia, Myelodysplasia, and Transplantation
1:15 PM-5:15 PM; S Hall A2
Hiroshi Katayama, MD
National Cancer Center
“An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A).” (Abstract 6112)
General Poster Session, Health Services Research
1:15 PM-5:15 PM; S Hall A2
Krina Patel, MD
The University of Texas M.D. Anderson Cancer Center
“Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.” (Abstract 8093)
General Poster Session, Lymphoma and Plasma Cell Disorders
1:15 PM-5:15 PM; S Hall A2
Alan Hanash, MD, PhD
Memorial Sloan-Kettering Cancer Center
“Effect of IL-22 on intestinal stem cells from GVHD and requirement for GVL.” (Abstract 6539)
General Poster Session, Leukemia, Myelodysplasia, and Transplantation
1:15 PM-5:15 PM; S Hall A2
Prashant Kapoor, MD
Mayo Clinc
“Does stage migration exist in active multiple myeloma (MM)?” (Abstract 8105)
General Poster Session, Lymphoma and Plasma Cell Disorders
1:15 PM-5:15 PM; S Hall A2
Wendy Chiang, MD
Tufts Medical Center
“Retrospective analysis of gene expression profiling and TTF-1 staining in cancer of unknown primary (CUP).” (Abstract 10579)
General Poster Session, Tumor Biology
1:15 PM-5:15 PM; S Hall A2
Peter Birks, MD
University of British Columbia
“Physical activity (PA) and physical function (PF) in adult cancer survivors (CS).” (Abstract 6085)
General Poster Session, Health Services Research
1:15 PM-5:15 PM; S Hall A2
Catherine Richards, MPH, MPhil
Mailman School of Public Health, Columbia University
“Influence of hospital characteristics on immediate breast reconstruction following mastectomy.” (Abstract 6118)
General Poster Session, Health Services Research
1:15 PM-5:15 PM; S Hall A2
Lauren Maeda, MD
Stanford University Medical Center
“Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.” (Abstract 8060)
General Poster Session, Lymphoma and Plasma Cell Disorders
1:15 PM-5:15 PM; S Hall A2
Christof Vulsteke, MD
University Hospitals Leuven
“The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).” (Abstract 1020)
Poster Discussion Session, Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
1:15 PM-5:15 PM; E450b
Justin Balko, PharmD, PhD
Vanderbilt University
“A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer.” (Abstract 1024)
Poster Discussion Session, Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
1:15 PM-5:15 PM; E450b
Michael Haas, MD
Klinikum Grosshadern and Comprehensive Cancer Center
“Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced” (Abstract 4023)
Poster Discussion Session, Gastrointestinal (Noncolorectal) Cancer
1:15 PM-5:15 PM; E450a